Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novogene CoSHSE:688315 +4.62%82 EV-to-FCF is 24.95 as of Sep. 22, 2026, which is 40% below its 10-year median of 41.25. GuruFocus rates SHSE:688315 with a GF Score™ of 82/100 and a GF Value™ of ¥15.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 329 Biotechnology companies, Novogene Co ranks worse than 62.61% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Novogene Co's Enterprise Value is ¥6,319 Mil.
Novogene Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ¥253 Mil. Therefore, Novogene Co's EV-to-FCF for today is 24.95.
The historical rank and industry rank for Novogene Co's EV-to-FCF or its related term are showing as below:
SHSE:688315'
s EV-to-FCF Range Over the Past 10 Years
Min: 12.77 Med: 41.25 Max: 155.62
Current: 24.95
During the past 11 years, the highest EV-to-FCF of Novogene Co was 155.62. The lowest was 12.77. And the median was 41.25.
SHSE:688315's EV-to-FCF is ranked worse than 62.61% of 329
companies
in the Biotechnology industry
Industry Median: 14.55
vs SHSE:688315: 24.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novogene Co's PE Ratio (TTM) for today is calculated as:
Novogene Co's share price for today is ¥19.02.
Novogene Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.374.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Novogene Co EV-to-FCF Related Terms
Novogene Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Novogene Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688315 vs VRTX, REGN, MRNA: EV-to-FCF Comparison
For the Biotechnology subindustry, Novogene Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novogene Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novogene Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Novogene Co's EV-to-FCF falls into.
Novogene Co's current Enterprise Value is ¥6,319 Mil.
Novogene Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥253 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novogene Co (SHSE:688315) has a EV-to-FCF of 24.95 as of Sep. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Novogene Co and its competitors. This is 40% below median its historical median of 41.25. Over the past decade, Novogene Co's EV-to-FCF has ranged from 12.77 to 155.62. According to the industry distribution chart, Novogene Co ranks #206 out of 329 companies in the Biotechnology industry, placing it in the top 62.6%.
Is Novogene Co's EV-to-FCF too high?
Novogene Co's current EV-to-FCF of 24.95 is 40% below median its 10-year median of 41.25. Over the past 10 years, this metric has ranged from a low of 12.77 to a high of 155.62. The Biotechnology industry median EV-to-FCF is 14.55. Novogene Co's value of 24.95 is 71.5% above this industry median. Based on the distribution chart, Novogene Co ranks #206 out of 329 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Novogene Co has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novogene Co ranks #206 out of 329 companies for EV-to-FCF. This places Novogene Co in the lower half of its industry. The industry median EV-to-FCF is 14.55. Novogene Co's value of 24.95 is 71.5% above this benchmark. Historically, Novogene Co's own EV-to-FCF has ranged from 12.77 to 155.62 over the past decade. While the company's 10-year median is 41.25 vs. the industry median of 14.55, Novogene Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.55, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novogene Co's current EV-to-FCF of 24.95 is 71.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Novogene Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novogene Co's current EV-to-FCF is 24.95, which is 40% below median its own 10-year median of 41.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥15.85, compared to a current price of ¥19.02 — trading 20% above its estimated fair value. The current EV-to-FCF is 24.95, which is 40% below median its 10-year median of 41.25 and 71.5% above the Biotechnology industry median of 14.55. Novogene Co's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current EV-to-FCF is 24.95 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novogene Co (SHSE:688315) Overvalued in 2026?
Based on GuruFocus' analysis, Novogene Co stock appears to be overvalued.
The current stock price of ¥19.02 is trading 20% above its estimated GF Value™ of ¥15.85.
GuruFocus considers Novogene Co to be Modestly Overvalued.
Key valuation signals for SHSE:688315:
EV-to-FCF: 24.95 (40% below median its 10-year median of 41.25)
GF Value™: ¥15.85 vs. price of ¥19.02 (20% above fair value)
Industry Position: 71.5% above the Biotechnology median (#206 of 329)
No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novogene Co Ltd is a Chinese life sciences company specializing in genomic sequencing and bioinformatics services. It provides next-generation sequencing, whole-genome sequencing, exome sequencing, RNA sequencing, epigenomics, and single-cell analysis, primarily to research institutions, universities, hospitals, pharmaceutical companies, and agricultural organizations. The company operates through two main segments: scientific research services, which generate the majority of revenue, and clinical testing services. Its customers include academic and government research bodies, medical institutions, and biotech and pharmaceutical firms. Novogene operates laboratories and facilities in China, the United States, the United Kingdom, Singapore, and the Netherlands, serving customers across Asia, Europe, and North America. Revenue is derived mainly from fee-for-service sequencing and bioinformatics analysis contracts, alongside equipment and reagent sales. The company was founded in 2011 and is headquartered in Beijing.
82GF Score
Get the complete analysis for SHSE:688315
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688315 has been successfully added to your 
